Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRDF Cardiff Oncology	$3.10 +2.6%	$3.09	$2.01 ▼ $5.64	$206.23M	1.61	1.19 million shs	1.50 million shs
FULC Fulcrum Therapeutics	$6.99 +9.9%	$5.61	$2.32 ▼ $10.13	$377.58M	2.41	958,908 shs	607,057 shs
IVA Inventiva	$3.29 -2.1%	$3.44	$1.53 ▼ $4.05	$314.73M	0.75	64,571 shs	5,444 shs
OTLK Oncobiologics	$1.71 +1.5%	$1.65	$0.87 ▼ $9.25	$57.23M	0.31	802,747 shs	353,356 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRDF Cardiff Oncology	0.00%	-18.64%	+7.64%	-17.33%	+24.00%
FULC Fulcrum Therapeutics	0.00%	+2.04%	+14.22%	+121.90%	+7.70%
IVA Inventiva	0.00%	-3.52%	+5.11%	+14.24%	+25.55%
OTLK Oncobiologics	0.00%	-6.32%	+3.96%	+12.91%	-75.88%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRDF Cardiff Oncology	1.4527 of 5 stars	3.5	0.0	2.9	0.0	0.6
FULC Fulcrum Therapeutics	0.143 of 5 stars	1.3	0.0	0.0	2.5	0.0
IVA Inventiva	2.0697 of 5 stars	3.4	2.0	0.0	1.7	0.6
OTLK Oncobiologics	1.3902 of 5 stars	3.4	1.0	1.9	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRDF Cardiff Oncology	3.00	Buy	$12.00	287.10% Upside
FULC Fulcrum Therapeutics	2.50	Moderate Buy	$6.29	-10.08% Downside
IVA Inventiva	2.80	Moderate Buy	$10.40	216.11% Upside
OTLK Oncobiologics	2.80	Moderate Buy	$9.60	463.05% Upside

Current Analyst Ratings Breakdown

Latest OTLK, CRDF, IVA, and FULC Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	CRDF Cardiff Oncology	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
6/6/2025	OTLK Oncobiologics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $21.00
5/29/2025	FULC Fulcrum Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$6.00 ➝ $9.00
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
5/23/2025	FULC Fulcrum Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$4.00 ➝ $12.00
5/20/2025	OTLK Oncobiologics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/15/2025	FULC Fulcrum Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Overweight	$10.00
5/9/2025	CRDF Cardiff Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$17.00 ➝ $18.00
4/4/2025	IVA Inventiva	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $9.00
3/28/2025	IVA Inventiva	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRDF Cardiff Oncology	$680K	303.30	N/A	N/A	$1.86 per share	1.67
FULC Fulcrum Therapeutics	$80M	4.72	N/A	N/A	$4.51 per share	1.55
IVA Inventiva	$9.95M	31.63	N/A	N/A	($1.21) per share	-2.72
OTLK Oncobiologics	N/A	N/A	N/A	N/A	($3.09) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRDF Cardiff Oncology	-$45.43M	-$0.92	N/A	N/A	N/A	-8,308.50%	-76.45%	-62.85%	8/14/2025 (Estimated)
FULC Fulcrum Therapeutics	-$9.73M	-$0.07	N/A	N/A	N/A	N/A	-0.20%	-0.19%	7/30/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	-$75.37M	-$0.91	N/A	N/A	N/A	N/A	N/A	-271.12%	8/13/2025 (Estimated)

Latest OTLK, CRDF, IVA, and FULC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q2 2025	OTLK Oncobiologics	-$0.55	-$0.40	+$0.15	-$1.50	$0.70 million	N/A
5/8/2025	Q1 2025	CRDF Cardiff Oncology	-$0.19	-$0.20	-$0.01	-$0.20	$0.09 million	$0.11 million
5/1/2025	Q1 2025	FULC Fulcrum Therapeutics	-$0.29	-$0.28	+$0.01	-$0.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRDF Cardiff Oncology	N/A	N/A	N/A	N/A	N/A
FULC Fulcrum Therapeutics	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
OTLK Oncobiologics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRDF Cardiff Oncology	N/A	6.22	6.22
FULC Fulcrum Therapeutics	N/A	28.71	28.71
IVA Inventiva	N/A	0.92	0.92
OTLK Oncobiologics	N/A	0.72	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRDF Cardiff Oncology	16.29%
FULC Fulcrum Therapeutics	89.83%
IVA Inventiva	19.06%
OTLK Oncobiologics	11.20%

Insider Ownership

Company	Insider Ownership
CRDF Cardiff Oncology	7.70%
FULC Fulcrum Therapeutics	7.00%
IVA Inventiva	32.00%
OTLK Oncobiologics	4.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRDF Cardiff Oncology	20	66.53 million	61.40 million	Optionable
FULC Fulcrum Therapeutics	100	53.98 million	50.20 million	Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
OTLK Oncobiologics	20	33.57 million	31.96 million	Optionable

OTLK, CRDF, IVA, and FULC Headlines

Recent News About These Companies

Oncobiologics, Inc. (NASDAQ:OTLK) Receives $9.60 Consensus Target Price from Analysts

June 19 at 1:15 AM | americanbankingnews.com

Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event

June 18, 2025 | globenewswire.com

Microsoft shares temp fix for Outlook crashes when opening emails

June 17, 2025 | bleepingcomputer.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Average Recommendation of "Moderate Buy" from Analysts

June 16, 2025 | marketbeat.com

CFA Institute 2025 Graduate Outlook Survey: Finance Top Career Choice

June 12, 2025 | tmcnet.com

Steve Wilks Pleased With Jets Defensive Outlook

June 12, 2025 | msn.com

Microsoft Outlook to block more risky attachments used in attacks

June 12, 2025 | bleepingcomputer.com

Outlook’s wet AMD treatment accepted by SMC for NHS Scotland

June 11, 2025 | pharmaceutical-technology.com

Outlook Therapeutics, Inc.: Outlook Therapeutics Announces SMC Recommendation of LYTENAVA (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | finanznachrichten.de

Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

June 10, 2025 | globenewswire.com

Highlights | Outlook Planet’s C³ Summit & Awards 2025

June 7, 2025 | outlookbusiness.com

Natural Gas Price Outlook – Natural Gas Continues to See Same Resistance Level

June 7, 2025 | fxempire.com

Oilers' Connor McDavid Offers Hilarious Outlook on Crucial Game 1 Moment

June 7, 2025 | msn.com

ChatGPT Business Features Now Include Gmail/Outlook Connectors, Meeting Transcriptions, New Pricing

June 7, 2025 | techrepublic.com

Outlook Therapeutics (NASDAQ:OTLK) Given New $21.00 Price Target at Ascendiant Capital Markets

June 6, 2025 | marketbeat.com

Outlook Therapeutics introduces Lytenava in Germany & UK for the treatment of wet AMD

June 4, 2025 | pharmabiz.com

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD

June 2, 2025 | globenewswire.com

Q3 EPS Estimate for Outlook Therapeutics Boosted by Analyst

May 31, 2025 | marketbeat.com

Brookline Capital Management Forecasts OTLK FY2026 Earnings

May 30, 2025 | marketbeat.com

Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Consensus Rating of "Moderate Buy" by Analysts

May 24, 2025 | marketbeat.com

Outlook Therapeutics announces public stock offering

May 24, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
Intel’s Turnaround May Be the Best Bet No One’s Watching
By Jeffrey Neal Johnson | May 30, 2025
View Intel’s Turnaround May Be the Best Bet No One’s Watching
Why SailPoint May Cruise Past Cybersecurity Rivals in 2025
By Nathan Reiff | June 18, 2025
View Why SailPoint May Cruise Past Cybersecurity Rivals in 2025

OTLK, CRDF, IVA, and FULC Company Descriptions

Cardiff Oncology NASDAQ:CRDF

$3.10 +0.08 (+2.65%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.10 0.00 (0.00%)

As of 06/20/2025 07:44 PM Eastern

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Fulcrum Therapeutics NASDAQ:FULC

$6.99 +0.63 (+9.91%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$7.00 +0.00 (+0.07%)

As of 06/20/2025 05:28 PM Eastern

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inventiva NASDAQ:IVA

$3.26 -0.09 (-2.83%)

As of 06/20/2025 04:00 PM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Oncobiologics NASDAQ:OTLK

$1.70 +0.03 (+1.49%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$1.70 0.00 (0.00%)

As of 06/20/2025 06:22 PM Eastern

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time